Cellectar Biosciences, Inc.
CLRB
$2.37
-$0.05-1.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.66% | -6.29% | -61.26% | -70.29% | -42.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.19% | -9.48% | -55.35% | -63.60% | -55.94% |
| Operating Income | -19.19% | 9.48% | 55.35% | 63.60% | 55.94% |
| Income Before Tax | -27.22% | 14.39% | -131.29% | 69.70% | -492.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.22% | 14.39% | -124.81% | 69.70% | -492.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.22% | 14.39% | -124.81% | 69.70% | -492.55% |
| EBIT | -19.19% | 9.48% | 55.35% | 63.60% | 55.94% |
| EBITDA | -19.70% | 9.52% | 55.50% | 63.81% | 56.14% |
| EPS Basic | 83.27% | 68.99% | 23.51% | 87.43% | -339.78% |
| Normalized Basic EPS | 83.27% | 68.99% | 21.30% | 87.43% | -339.75% |
| EPS Diluted | 83.19% | 68.99% | 23.51% | 88.38% | 37.54% |
| Normalized Diluted EPS | 83.27% | 68.99% | 21.30% | 87.29% | -359.81% |
| Average Basic Shares Outstanding | 660.31% | 176.05% | 193.89% | 141.15% | 34.74% |
| Average Diluted Shares Outstanding | 660.31% | 176.05% | 193.89% | 138.37% | 28.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |